Akili, Inc.
AKLI
$0.00
Change (1 day)
$1.25
Year High
$0.19
Year Low
Categories
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
P/E ratio for Akili, Inc. (AKLI)
P/E ratio as of 2023: -0.64
According to Akili, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.64. At the end of 2022 the company had a P/E ratio of -4.20.
P/E ratio history for Akili, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.64 |
| 2022 | -4.20 |
| 2021 | -5.12 |
| 2020 | -30.69 |
| 2019 | -38.15 |